ASLAN Pharmaceuticals Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study

NEXT STORY
Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020
PREV STORY
DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms 
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Worldwide Pharmacogenomics Markets, 2019-2028 – Global Market to Reach $8.98 Billion by 2028

author_avatar
NASDAQ Market News

FIT Biotech Oy: Conversion of FIT Biotech Oy’s Convertible Capital Notes into shares

FIT Biotech Oy Company release February 22, 2018 at 3:00 PM EET Conversion of ...

author_avatar
NASDAQ Market News

Calithera Biosciences to Host R&D Day and Webcast on October 5, 2018

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: ...

author_avatar
NASDAQ Market News